Lisbon, Portugal, 31st October 2017 biosurfit SA (“biosurfit”), the in vitro point-of-care (PoC) diagnostics company, announces that its spinit® HbA1c point-of-care test has successfully achieved both IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) certification and NGSP (National Glycohemoglobin Standardization Program) certification.

The IFCC maintains the JCTLM (Joint Committee for Traceability in Laboratory Medicine) endorsed reference measurement procedure for HbA1c, accepted worldwide as the analytical control for traceability of HbA1c measurement.


The NGSP certification is awarded to systems that yield results sufficiently accurate and precise to be comparable to those reported in the Diabetes Control and Complications Trial (DCCT).

The recent awarding of both IFCC and NGSP certifications, clearly demonstrate that the spinit® HbA1c test meets all the extremely demanding requirements set by two independent certifying bodies.

Glycated hemoglobin (HbA1c) testing is globally recognised as the gold standard in monitoring of diabetic patients, enabling more complete control of their disease management. The spinit® HbA1c test offers precise and accurate results in less than 6 minutes from just 5μL of blood, using a simple system capable of performing further blood tests.

João Garcia da Fonseca, CEO of biosurfit, commented:“It is with immense pride and honour that biosurfit receives these certifications. We believe this is the recognition of our hard and intense work along the years to make spinit® a new reference in the way of performing blood analysis.”


For enquiries please contact:

biosurfit SA
João Garcia da Fonseca, Chief Executive Officer
Daniel Neves, Chief Marketing Officer
Tel: +351 218 860 169

Notes to editors
About biosurfit and spinit®

biosurfit is a fast-growing and highly innovative commercial stage European medical diagnostics company focused on the development and manufacture of breakthrough technologies for the in vitro diagnostic (IVD) market. Its lead product spinit®, which was commercially launched in 2014, addresses an unmet need for fast, precise, reliable, easy-to-use blood analysis for medical testing in the point-of-care setting.